FDA is alerting health care professionals about reports of an increased rate of adverse events, including deaths, in clinical trials with the cancer medicine Zydelig (idelalisib) in combination with other cancer medicines.
Urologic oncologist Wayne Brisbane thought his patient might be a good candidate for focal therapy.
